SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

BioNTech SE

(Name of Issuer)

Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)

(Title of Class of Securities)

09075V102

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

09075V102

Names of Reporting Persons

ATHOS KG

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

GERMANY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 101,702,378.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 101,702,378.00

Aggregate Amount Beneficially Owned by Each Reporting Person

101,702,378.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

40.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP Number(s):

09075V102

Names of Reporting Persons

AT Impf GmbH

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

GERMANY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 101,702,378.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 101,702,378.00

Aggregate Amount Beneficially Owned by Each Reporting Person

101,702,378.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

40.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP Number(s):

09075V102

Names of Reporting Persons

Thomas Maier

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

GERMANY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 101,702,378.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 101,702,378.00

Aggregate Amount Beneficially Owned by Each Reporting Person

101,702,378.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

40.2 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

BioNTech SE

(b)

Address of issuer's principal executive offices:

AN DER GOLDGRUBE 12, MAINZ, GERMANY, 55131.

Item 2.

(a)

Name of person filing:

This Amendment No. 6 to Schedule 13G is being jointly filed by ATHOS KG, AT Impf GmbH and Thomas Maier, each of the foregoing, a "Reporting Person," and collectively, the "Reporting Persons." The sole member of AT Impf GmbH is ATHOS KG and, as a result, ATHOS KG is deemed to be the beneficial owner of the securities held by AT Impf GmbH. Thomas Maier is the general partner (komplementar) of ATHOS KG. The limited partners (kommanditisten) of ATHOS KG are members of the families of Thomas and Andreas Strungmann. The Reporting Persons have entered into a Joint Filing Agreement, dated February 11, 2022, which was attached as Exhibit 1 to Amendment No. 2 to Schedule 13G filed by the Reporting Persons, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

(b)

Address or principal business office or, if none, residence:

The address of the principal business office of each of the Reporting Persons is Bergfeldstrasse 9 83607 Holzkirchen.

(c)

Citizenship:

ATHOS KG is a German limited partnership (Kommanditgesellschaft); AT Impf GmbH is a German limited liability company (Gesellschaft mit beschrankter Haftung); and Mr. Maier is a citizen of Germany.

(d)

Title of class of securities:

Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)

(e)

CUSIP No.:

09075V102

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

See the responses to Item 9 on the attached cover pages.

(b)

Percent of class:

See the responses to Item 11 on the attached cover pages, which were calculated based on 252,884,261 ordinary shares of the Issuer outstanding as of March 31, 2026, as reported by the Issuer in its Form 6-K filed with the Securities and Exchange Commission on May 5, 2026.

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See the responses to Item 5 on the attached cover pages.

(ii) Shared power to vote or to direct the vote:

See the responses to Item 6 on the attached cover pages.

(iii) Sole power to dispose or to direct the disposition of:

See the responses to Item 7 on the attached cover pages.

(iv) Shared power to dispose or to direct the disposition of:

See the responses to Item 8 on the attached cover pages.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

See responses to Item 2(a) and Item 4.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

See responses to Item 2(a) and Item 4.

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ATHOS KG

Signature:	/s/ Thomas Maier
Name/Title:	Thomas Maier (Authorized Signatory)
Date:	05/14/2026

Signature:	/s/ Stephan Sperber
Name/Title:	Stephan Sperber (Authorized Signatory)
Date:	05/14/2026

AT Impf GmbH

Signature:	/s/ Thomas Maier
Name/Title:	Thomas Maier (Authorized Signatory)
Date:	05/14/2026

Signature:	/s/ Stephan Sperber
Name/Title:	Stephan Sperber (Authorized Signatory)
Date:	05/14/2026

Thomas Maier

Signature:	/s/ Thomas Maier
Name/Title:	Thomas Maier
Date:	05/14/2026

Amendment: SEC Form SCHEDULE 13G/A filed by BioNTech SE